Company Overview - Aoyang Health's closing price on August 12 was 4.22 yuan, down 1.63%, with a rolling PE ratio of 114.10 times and a total market value of 3.231 billion yuan [1] - The company operates in the medical services, pharmaceutical distribution, and biotechnology sectors, with main products including medical services and pharmaceutical logistics [1] - As of March 31, 2025, Aoyang Health had 53,714 shareholders, a decrease of 3,624 from the previous period, with an average holding value of 352,800 yuan and an average holding of 27,600 shares per shareholder [1] Financial Performance - In the first quarter of 2025, Aoyang Health reported revenue of 452 million yuan, a year-on-year decrease of 22.27%, and a net profit of 18.4992 million yuan, down 39.82% year-on-year, with a gross margin of 15.09% [2] - The company's PE ratio (TTM) is 114.10, while the industry average is 48.17 and the industry median is 63.54 [2] Industry Comparison - Aoyang Health ranks 39th in the medical services industry based on PE ratio, which has an average of 48.17 and a median of 63.54 [1] - The company has been recognized in various awards, including being ranked 32nd in the non-public hospital top 100 list and 2nd among county-level non-public hospitals in China [1]

Core Viewpoint - Yirui Technology's stock closed at 93.5 yuan, up 5.79%, with a rolling PE ratio of 39.92, marking a new low in 39 days, and a total market value of 18.72 billion yuan [1] Company Summary - Yirui Technology specializes in the research, production, sales, and service of digital X-ray detectors, high-voltage generators, combination ray sources, and tubes [1] - The main products include the universal series, dental series, mammography series, radiotherapy series, industrial series, high-voltage generators, and combination ray sources [1] - As of the first quarter of 2025, the company reported operating revenue of 482 million yuan, a year-on-year decrease of 1.92%, and a net profit of 143 million yuan, a year-on-year increase of 2.74%, with a gross profit margin of 48.92% [1] Industry Summary - The average PE ratio for the medical device industry is 56.56, with a median of 39.76, placing Yirui Technology at 77th in the industry ranking [1] - As of the first quarter of 2025, 51 institutions hold shares in Yirui Technology, with a total of 17.0041 million shares valued at 1.49 billion yuan [1] - The industry average market value is 11.897 billion yuan, while the median market value is 5.767 billion yuan [2]

Core Viewpoint - Antu Biology's stock closed at 42.34 yuan, up 3.39%, with a rolling PE ratio of 21.22, marking a new low in 88 days, and a total market capitalization of 24.194 billion yuan [1] Company Summary - Antu Biology specializes in the research, manufacturing, integration, and service of in vitro diagnostic reagents and instruments, with key products including immunodiagnostic reagents, microbiological testing reagents, molecular diagnostic reagents, biochemical reagents, and instruments [1] - As of March 31, 2025, the number of shareholders reached 34,163, an increase of 3,382 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The latest quarterly report for Q1 2025 shows revenue of 996 million yuan, a year-on-year decrease of 8.56%, and a net profit of 270 million yuan, down 16.76%, with a gross profit margin of 65.07% [1] Industry Summary - The average PE ratio for the medical device industry is 56.56, with a median of 39.76, placing Antu Biology at 45th in the industry ranking [1] - The industry average market capitalization is 118.97 billion yuan, while the median is 57.67 billion yuan [2]

Core Viewpoint - Chongqing Bank's stock closed at 10.21 yuan, down 1.45%, with a rolling PE ratio of 6.82 times and a total market value of 35.476 billion yuan [1] Group 1: Financial Performance - For Q1 2025, the company reported operating revenue of 3.581 billion yuan, a year-on-year increase of 5.30% [3] - The net profit for the same period was 1.624 billion yuan, also reflecting a year-on-year growth of 5.33% [3] Group 2: Market Position - The average PE ratio for the banking industry is 7.45 times, with a median of 6.58 times, placing Chongqing Bank at 28th in the industry ranking [1][3] - The company's PE (TTM) is 6.82, while the static PE is 6.93, and the price-to-book ratio is 0.66 [3] Group 3: Shareholder Information - As of March 31, 2025, Chongqing Bank had 35,943 shareholders, a decrease of 4,248 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1]

Company Overview - Huadian International's closing price on August 11 was 5.41 yuan, down 1.10%, with a rolling PE ratio of 10.22 times and a total market capitalization of 59.004 billion yuan [1] - The company's main business includes power generation, heating, coal sales, and other related services, with electricity and heat products as its primary offerings [1] Financial Performance - For the first quarter of 2025, Huadian International reported operating revenue of 26.577 billion yuan, a year-on-year decrease of 14.14%, and a net profit of 1.930 billion yuan, a year-on-year increase of 3.66%, with a gross profit margin of 10.73% [1] Industry Comparison - The average PE ratio for the power industry is 23.07 times, with a median of 19.67 times, placing Huadian International at 15th in the industry ranking [1] - The company has a total of 57 institutional holders, including 57 funds, with a combined holding of 162.4649 million shares valued at 0.889 billion yuan [1] Valuation Metrics - Huadian International's PE (TTM) is 10.22, while the industry average is 23.07, indicating a significant undervaluation compared to peers [2] - The company's price-to-book ratio is 1.33, compared to the industry average of 2.17 [2]

8月11日，美好医疗今日收盘20.38元，上涨1.75%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到32.42倍，创49天以来新低，总市值115.94亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均56.56倍，行业中值39.76倍，美好医疗排 名第64位。 最新一期业绩显示，2025年一季报，公司实现营业收入2.96亿元，同比5.05%；净利润5187.50万元，同 比-10.62%，销售毛利率39.28%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13美好医疗32.4231.873.29115.94亿行业平均 56.5652.664.92118.97亿行业中值39.7639.192.9457.67亿1九安医疗11.2811.400.89190.28亿2英科医疗 15.1416.331.35239.25亿3山东药玻16.1616.211.86152.83亿4振德医疗16.7615.801.0760.86亿5新华医疗 17.1715.911.40110.05亿6奥美医疗17.1816.831.7762.06亿7九强生物17.8916.632.1988.59亿8康德 ...

8月11日，中集车辆今日收盘8.78元，上涨2.09%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到16.47倍，总市值164.55亿元。 从行业市盈率排名来看，公司所处的汽车整车行业市盈率平均34.88倍，行业中值23.23倍，中集车辆排 名第12位。 股东方面，截至2025年3月31日，中集车辆股东户数36558户，较上次增加1451户，户均持股市值35.28 万元，户均持股数量2.76万股。 中集车辆(集团)股份有限公司的主营业务是半挂车、专用车上装及整车、冷藏厢式车厢体及整车的生 产、制造与销售。公司的主要产品是普通半挂车、罐车、上装产品、底盘及牵引车。公司运营着"通 华"、"华骏"、"深扬帆"、"瑞江汽车"、"凌宇汽车"、"梁山东岳"等行业知名品牌；在北美，公司运营 着"Vanguard"、"CIE"等知名品牌；在欧洲，公司运营着"SDC"和"LAG"两个历史悠久的知名品牌。 序号股票简称PE(TTM)PE(静)市净率总市值(元)5中集车辆16.4715.161.13164.55亿行业平均 34.8839.834.66925.67亿行业中值23.2326.412.58212.15亿1 ...

8月11日，五洲医疗今日收盘42.56元，上涨1.19%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到81.02倍，创480天以来新低，总市值28.94亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均56.56倍，行业中值39.76倍，五洲医疗排 名第101位。 股东方面，截至2025年7月31日，五洲医疗股东户数7255户，较上次增加848户，户均持股市值35.28万 元，户均持股数量2.76万股。 安徽宏宇五洲医疗器械股份有限公司的主营业务是一次性使用无菌输注类医疗器械的研发、制造和销 售，以及其他诊断、护理等相关医疗用品的集成供应。公司的主要产品是注射器、安全型注射器、胰岛 素注射器、配药注射器、输液器、输血器、注射针、静脉输液针、采血针、胰岛素注射笔用针头、安全 注射针、安全采血针、血压表、面罩。 最新一期业绩显示，2025年一季报，公司实现营业收入1.04亿元，同比15.59%；净利润563.45万元，同 比-43.00%，销售毛利率14.62%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13五洲医疗81.0272.413.7728.94亿行业平均 56. ...

Core Viewpoint - Samsung Medical's stock price increased by 4.56% to 23.61 yuan, with a rolling PE ratio of 13.91, marking a new low in 55 days, and a total market capitalization of 33.178 billion yuan [1][2] Company Summary - Samsung Medical's main business segments include smart power distribution and medical services, with key products such as smart meters, high-end gateway meters, smart terminals, power boxes, communication modules, and various integrated solutions [1] - The company has received multiple accolades, including being recognized as a national-level intellectual property demonstration enterprise and a provincial key enterprise research institute [1] Financial Performance - For the first quarter of 2025, Samsung Medical reported revenue of 3.631 billion yuan, a year-on-year increase of 20.03%, and a net profit of 489 million yuan, reflecting a year-on-year growth of 34.33% [2] - The company's gross profit margin stands at 28.90% [2] Industry Comparison - In the electric grid equipment industry, Samsung Medical's PE ratio of 13.91 is significantly lower than the industry average of 38.47 and the median of 41.87 [2] - The company ranks 34th in terms of PE ratio within its industry [1]

Company Overview - Xishan Technology's closing price on August 8 was 72.56 yuan, up 1.94%, with a rolling PE ratio of 39.18, marking a new low in 207 days, and a total market capitalization of 3.301 billion yuan [1] - The company operates in the surgical medical device sector, focusing on the research, manufacturing, sales, and service of surgical instruments, including surgical power devices, endoscopic systems, and energy surgical equipment [1] Financial Performance - For the first quarter of 2025, Xishan Technology reported revenue of 65.8771 million yuan, a year-on-year decrease of 11.20%, and a net profit of 11.4768 million yuan, down 55.66% year-on-year, with a gross profit margin of 67.64% [1] Industry Comparison - The average PE ratio for the medical device industry is 55.70, with a median of 39.08, placing Xishan Technology at the 77th position in the industry ranking [1] - The company’s static PE ratio is 33.46, and its price-to-book ratio is 1.91 [2]